On Wednesday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $3.21 which represents a decrease of $-0.08 or -2.43% from the prior close of $3.29. The stock opened at $3.28 and ...

Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...